RNXT RenovoRx, Inc. stock chart & analysis
Conviction 36HealthcareScan · Fri, Nov 6, 2026RenovoRx, Inc. (RNXT) closed at $1.13 (-5.04%) on Nov 6, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 38, RS Rating 76, -55.8% from its 52-week high, +36.3% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Wed, Sep 30, 2026 · quarterly.
RNXT technical analysis
Trend
RNXT's moving averages are mixed — no clean uptrend or downtrend. It closed 25.9% below the 50-day ($1.54) and 3.3% above the 200-day ($1.11). ADX(14) at 23 points to a moderate trend. It meets 5 of 8 trend-template criteria.
Momentum
RSI(14) is 38, in the bearish half of its range. MACD crossed below its signal line on the latest session. A bullish MACD divergence is in place. Its RS Rating of 76 puts its weighted 12-month performance ahead of about 76% of the US market.
Volume and volatility
Volume on the latest session ran 7.1× its 20-day average. It trades about $549,608 a day on average. ATR(14) is $0.1331, 11.6% of price — its typical daily range. On-balance volume is trending down.
Key levels
The chart pattern's support is $1.16 and its resistance $1.79. The 52-week range is $0.7006 to $2.59; price is 55.8% below the high and 63.4% above the low. The VWAP anchored at the 52-week high is $1.76, above price.
Performance
RNXT returned -13.9% (1 week), -13.9% (1 month), -1.3% (3 months), +32.6% (6 months), +11.2% (1 year), +36.3% (year to date).
About RenovoRx, Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Pharmaceutical Preparations · Listed 2021 · 17 employees
Recent news
- RenovoRx, Inc.: Ownership stake amendedSEC EDGAR · Fri, Nov 6, 2026
- RenovoRx Inc (RNXT) (Q3 2026) Earnings Call Highlights: Record Revenue, Expanding Commercial ...Yahoo Finance · Fri, Nov 6, 2026
- RenovoRx earnings missed, revenue topped estimates By Investing.comInvesting.com UK · Thu, Nov 5, 2026
- RenovoRx, Inc. (RNXT) Reports Q3 Loss, Tops Revenue EstimatesYahoo Finance · Thu, Nov 5, 2026
- RenovoRx Q3 2026 Earnings Call TranscriptBenzinga · Thu, Nov 5, 2026
- RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 MillionYahoo Finance · Thu, Nov 5, 2026
- 26 cancer centers are active RenovoRx customers; more than 65 are in its sales pipeline.Stock Titan · Thu, Nov 5, 2026
Insider activity
SEC Form 4 transactions in RNXT · open-market 1 buy
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
VOLL MARK Chief Financial Officer · Common Stock · 2026-09-10 | Grant | 80K | — | 2026-09-10 | 2026-09-15 |
VOLL MARK Chief Financial Officer · Common Stock · 2026-05-19 | Other | — | — | 2026-05-19 | 2026-05-21 |
VOLL MARK Chief Financial Officer · Common Stock · 2026-05-19 | Buy | 25K | $20K | 2026-05-19 | 2026-05-21 |
SEC filings
EDGAR filings in RNXT · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.